Cogent Biosciences COGT 深 沪
等待开盘 08-27 09:30:00 美东时间
36.72
-0.080
-0.22%
华盛通- 最 高37.12
- 今 开36.49
- 成交量 106.28万股
- 最 低 36.282
- 昨 收 36.80
- 总市值 63.72亿
- 52周最高 43.73
- 市盈率 静 --
- 换手率 0.61%
- 52周最低 11.60
- 委 比 27.48%
- 总股本 1.74亿
- 历史最高 43.73
- 量 比 0.64
- 振 幅 2.28%
- 历史最低 3.67
- 每 手 1
- 风险率 9.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.
08-18 00:08
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
财报速睇 | Cogent Biosciences, Inc. 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.96亿美元，同比亏损扩大29.7%
华盛资讯8月11日讯，Cogent Biosciences, Inc.公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.96亿美元，同比亏损扩大29.7%。
08-11 05:54
Cogent Biosciences Q2 EPS $(0.52) Beats $(0.57) Estimate
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 1.89 percent increase over losses of $(0.53) per share from the same period last year.
08-11 05:15
财报速睇 | Cogent Biosciences, Inc. 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.96亿美元，同比亏损扩大29.7%
华盛资讯8月10日讯，Cogent Biosciences, Inc.公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.96亿美元，同比亏损扩大29.7%。
08-10 20:20
If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 28.96% on an annualized basis producing an average annual return of 40.76%. Currently, Cogent Biosciences has a market capitalization of $7.23 billion. Buying $100 In COGT: If an investor had bought $100 of COGT st...
08-08 05:00
美股大行评级 | Susquehanna上调美光目标价从600美元升至1750美元；戴尔、MongoDB、网泰信息存储、Nextpower、Okta等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从7美元升至7.5美元；Susquehanna：维持美光科技"积极"评级，目标价从600美元升至1750美元
06-01 14:11
美股夜盘 | Summit Therapeutics Inc涨21.09%，Revolution Medicines涨20.27%
Summit Therapeutics Inc涨21.09%；Revolution Medicines涨20.27%；泰勒·莫里森家涨20.00%
06-01 09:01
Cogent Biosciences Says FDA Accepts NDA For Bezuclastinib In Combination With Sunitinib For Patients With GIST With PDUFA Target Action Date Of November 30
NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30,
05-28 20:21
